Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Free Cash Flow (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Free Cash Flow for 5 consecutive years, with -$15.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Free Cash Flow fell 21.66% to -$15.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$63.4 million, a 34.27% decrease, with the full-year FY2024 number at -$56.2 million, down 68.32% from a year prior.
  • Free Cash Flow was -$15.2 million for Q3 2025 at Werewolf Therapeutics, roughly flat from -$15.2 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$2.2 million in Q2 2022 to a low of -$18.9 million in Q1 2025.
  • A 5-year average of -$11.9 million and a median of -$12.5 million in 2024 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: surged 79.38% in 2022, then crashed 403.48% in 2023.
  • Werewolf Therapeutics' Free Cash Flow stood at -$13.1 million in 2021, then grew by 5.37% to -$12.4 million in 2022, then surged by 58.38% to -$5.2 million in 2023, then plummeted by 174.01% to -$14.1 million in 2024, then dropped by 7.28% to -$15.2 million in 2025.
  • Per Business Quant, the three most recent readings for HOWL's Free Cash Flow are -$15.2 million (Q3 2025), -$15.2 million (Q2 2025), and -$18.9 million (Q1 2025).